Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

She works as both a clinician and a dermatological researcher, specializing in skin cancer prevention and ...

Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves ...

This is the 11th year that Little Eric’s Foundation participated, as an organization, in Cycle for Survival in New York City.

Triplet therapy with bortezomib, lenalidomide and dexamethasone — a regimen often referred to as VRd — is a current standard ...

A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient ...

Results were announced from a trial evaluating durvalumab with FLOT chemo as perioperative treatment for resectable early stage gastric/GEJ cancers.

Memorial Hospital for Cancer and Allied Diseases and Memorial Sloan Kettering Cancer Center have jointly developed new nonsteroid selective androgen receptor modulators (SARMs) and radiolabeled ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

Gary A. Ulaner, M.D., Ph.D., F.A.C.N.M. is the director of molecular imaging and therapy at Hoag Family Cancer Institute and ...